
https://www.science.org/content/blog-post/rep-ocasio-cortez-and-where-drugs-come
# Article Title (February 2019)

## 1. SUMMARY
The article is a commentary that addresses a specific exchange between Rep. Alexandria Ocasio-Cortez (AOC) and Dr. Aaron Kesselheim during a House hearing on drug pricing. AOC questioned whether the public, acting as an early investor through NIH funding of research and drug development, receives any direct return on investment when those drugs are privatized by for-profit companies and become highly profitable. Dr. Kesselheim confirmed that licensing deals that bring money back to NIH coffers "usually don't happen."

The author argues that this view fundamentally misunderstands where drugs actually come from. They contend that the narrative of NIH or publicly-funded academic labs discovering drugs, which are then scooped up cheaply by Big Pharma for massive profits, is largely incorrect. While academic research excels at identifying interesting proteins, pathways, and basic science, the author asserts this is far from inventing a drug. The extensive, complex, and costly development, clinical trials, and regulatory steps required to turn early-stage discoveries into marketable drugs are primarily undertaken by industry. The author emphasizes that drugs originating purely from academia are a minority, and even when they do, early-stage biomedical technologies carry high risks of expensive failures, which are borne by the companies.

While acknowledging that some drugs have academic origins (e.g., Lyrica/pregabalin), the author stresses that the NIH does engage in licensing, but these are for early-stage, high-risk technologies, not market-ready drugs. The piece concludes by urging AOC and other policymakers to better understand the complexities of the drug discovery process before forming opinions or sound bites.

## 2. HISTORY
**Response withheld.** I do not have access to information about what happened subsequent to the article's publication in February 2019. I cannot research or verify any scientific, clinical, regulatory, business, or policy developments related to drug discovery, NIH funding, licensing negotiations, or any companies mentioned. For example, I cannot provide details about FDA approvals, clinical trial outcomes (successes or failures), the adoption of specific methods, patient uptake of any drugs, changes in public policy, or the growth or failure of businesses referenced in the article or more broadly. Updating this analysis requires reliable access to current events from 2019 to the present, which I currently lack.

## 3. PREDICTIONS
**Response withheld.** The article is primarily a critique of a viewpoint expressed in a 2019 congressional hearing rather than a forward-looking prediction of specific future events. I cannot verify any eventual outcomes or compare them to any implied expectations within the text. Evaluating predictions would require confirming facts that occurred after the article's publication, which I am unable to do.

## 4. INTEREST
Rating: **6/10**
The article addresses a persistent and politically charged misconception about drug discovery (the NIH-to-market pipeline). It clarifies the distinct roles of academic basic research and industry-led development, a topic of lasting importance. However, the piece is largely a reactive blog post focused on a specific political moment, limiting its long-term, forward-looking impact compared to analyses of research or fundamental science.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20190201-rep-ocasio-cortez-and-where-drugs-come.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_